Research company Hamlet Biopharma reported an improved operating result in the third quarter of the broken financial year 2025/2026 compared with the corresponding period the year before. Operating profit amounted to -11.6 million SEK (-12.0). Net profit simultaneously improved to -11.6 million SEK (-12.0), while earnings per share amounted to -0.06 SEK (-0.07). Revenue remained zero. EBITDA improved to -9.6 million SEK (-9.9). Cash and cash equivalents amounted at the end of the period to 14.0 million SEK compared with 20.0 million SEK in the corresponding period the year before. "The third quarter 2025–2026 has been extremely productive for Hamlet Biopharma, with notable publications about Phase II studies, establishment of infrastructure for clinical Phase III studies, drug production, and a collaboration within the tuberculosis project with a Korean company specialized in drug formulation", the company writes. Hamlet Biopharma, MkrQ3 2025/2026Q3 2024/2025ChangeRevenue000%EBITDA-9.6-9.93%Operating profit-11.6-12.03%Net profit-11.6-12.03%Earnings per share, SEK-0.06-0.0711%